Immunogenic peptides binding to HLA class I (e.g., HLA-A, B, C) are presented by nucleated cells and are recognized by cytotoxic CD8+ T cells; those binding to HLA class II (e.g., HLA-DR, DP, DQ) on the surface of the antigen-presenting cells [e.g., dendritic cells, macrophages, or B cells] and tumor cells display antigen peptide to CD4+ T cells, thus providing help to the effector cells such as innate immune cells, B cells and CD8 T cells [12]. Here, CD4 is linked to neoplasm.